657 results on '"Hunter, Zachary R"'
Search Results
2. Therapeutic activation of G protein-coupled estrogen receptor 1 in Waldenström Macroglobulinemia
3. Response and survival predictors in a cohort of 319 patients with Waldenström macroglobulinemia treated with ibrutinib monotherapy
4. Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia
5. Expression of the prosurvival kinase HCK requires PAX5 and mutated MYD88 signaling in MYD88-driven B-cell lymphomas
6. Identification of robust predictors for ibrutinib response by multi-omics in MYD88 mutated Waldenstrom Macroglobulinemia
7. CXCR4 in Waldenström’s Macroglobulinema: chances and challenges
8. Human MYD88L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cells
9. CXCR4S338X clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemia
10. New developments in the diagnosis and characterization of Waldenström’s macroglobulinemia
11. Signal Inhibitors in Waldenstrom’s Macroglobulinemia
12. Genetic and Signaling Abnormalities in Waldenstrom’s Macroglobulinemia
13. BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism
14. Extracellular vesicle–mediated transfer of constitutively active MyD88L265P engages MyD88wt and activates signaling
15. Identification of robust predictors for ibrutinib response by multiomics in MYD88-mutated Waldenström macroglobulinemia
16. Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia
17. SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas
18. Data from Molecular and Cellular Effects of NEDD8-Activating Enzyme Inhibition in Myeloma
19. Supplementary Figures 1-3, Table 1 from Molecular and Cellular Effects of NEDD8-Activating Enzyme Inhibition in Myeloma
20. New developments in the diagnosis and characterization of Waldenström’s macroglobulinemia
21. Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia
22. HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib
23. Future therapeutic options for patients with Waldenström macroglobulinemia
24. Contributors
25. Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma
26. Dysfunctions of innate and adaptive immune tumor microenvironment in Waldenström macroglobulinemia
27. The ERK1/2 Regulator WNK2 Shows Novel Alternative Splicing Aberrations That Support Tumor Growth in MYD88 Mutated Waldenström's Macroglobulinemia
28. Identification of Robust Predictors for Ibrutinib Response By Multi-Omic Genomics in MYD88 Mutated Waldenstrom's Macroglobulinemia
29. Clinical Effectiveness and Long-Term Serologic Responses of COVID-19 Vaccination in Patients with Multiple Myeloma and Waldenström Macroglobulinemia
30. Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinemia
31. Multi-Omic Analysis of 253 Untreated Patients with Waldenström's Macroglobulinemia Reveals Clinically and Genomically Distinct Disease Subtypes and a Model for Disease Progression
32. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenström macroglobulinemia
33. The genomic landscape of Waldenström macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis
34. IBCL-519 Correlation Between Familial Waldenström Macroglobulinemia Clusters With Clinical Features Complications, and Outcomes in 1000 patients: A Single-Center Retrospective Cohort Study
35. Correlation Between Familial Waldenström Macroglobulinemia Clusters With Clinical Features, Complications, and Outcomes in 1000 patients: A Single-Center Retrospective Cohort Study
36. Comparing apples to oranges: A commentary on the Mayo study of MYD88 significance in Waldenstromʼs macroglobulinemia.
37. MYD88 mutations can be used to identify malignant pleural effusions in Waldenström macroglobulinaemia
38. MYD88 wild‐type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival
39. A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomas
40. Patients With Waldenström Macroglobulinemia Commonly Present With Iron Deficiency and Those With Severely Depressed Transferrin Saturation Levels Show Response to Parenteral Iron Administration
41. MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction
42. Ibrutinib penetrates the blood brain barrier and shows efficacy in the therapy of Bing Neel syndrome
43. To select or not to select? The role of B‐cell selection in determining the MYD88 mutation status in Waldenström Macroglobulinaemia
44. Familial Disease Predisposition Impacts Treatment Outcome in Patients With Waldenström Macroglobulinemia
45. Dysfunctions of innate and adaptive immune tumor microenvironment in Waldenström macroglobulinemia.
46. Signal Inhibitors in Waldenstrom’s Macroglobulinemia
47. Genetic and Signaling Abnormalities in Waldenstrom’s Macroglobulinemia
48. Additional file 1 of Therapeutic activation of G protein-coupled estrogen receptor 1 in Waldenström Macroglobulinemia
49. Additional file 2 of Therapeutic activation of G protein-coupled estrogen receptor 1 in Waldenström Macroglobulinemia
50. Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.